Martin-Castillo, B., Lopez-Bonet, E., Buxó, M., Dorca, J., Tuca-Rodríguez, F., Ruano, M. A., . . . Menendez, J. A. (2015). Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. Impact Journals LLC.

Martin-Castillo, Begoña, Eugeni Lopez-Bonet, Maria Buxó, Joan Dorca, Francesc Tuca-Rodríguez, Miguel Alonso Ruano, Ramon Colomer, and Javier A. Menendez. Cytokeratin 5/6 Fingerprinting in HER2-positive Tumors Identifies a Poor Prognosis and Trastuzumab-resistant Basal-HER2 Subtype of Breast Cancer. Impact Journals LLC, 2015.

Martin-Castillo, Begoña, et al. Cytokeratin 5/6 Fingerprinting in HER2-positive Tumors Identifies a Poor Prognosis and Trastuzumab-resistant Basal-HER2 Subtype of Breast Cancer. Impact Journals LLC, 2015.